本帖最后由 老马 于 2013-3-13 13:43 编辑
. V& r# H+ o- K6 R1 j6 }# k2 K: I
# e$ v6 I$ D, z7 Y. X. N9 C健择（吉西他滨）+顺铂+阿瓦斯汀( L3 N9 w% I1 R
Gemzar +Cisplatin + Avastin- a r' l8 Y u5 \7 P+ R
http://annonc.oxfordjournals.org/content/21/9/1804.full5 N4 N' b- H, E |
Overall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL) 3 t& ?) O2 q8 F g0 |
Patients and methods: Patients (n = 1043) received cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to six cycles plus bevacizumab 7.5 mg/kg (n = 345), bevacizumab 15 mg/kg (n = 351) or placebo (n = 347) every 3 weeks until progression. Primary end point was progression-free survival (PFS); OS was a secondary end point. - K4 e4 F+ O% T# {: S- T0 M
Results: Significant PFS prolongation with bevacizumab compared with placebo was maintained with longer follow-up {hazard ratio (HR) [95% confidence interval (CI)] 0.75 (0.64–0.87), P = 0.0003 and 0.85 (0.73–1.00), P = 0.0456} for the 7.5 and 15 mg/kg groups, respectively. Median OS was >13 months in all treatment groups; nevertheless, OS was not significantly increased with bevacizumab [HR (95% CI) 0.93 (0.78–1.11), P = 0.420 and 1.03 (0.86–1.23), P = 0.761] for the 7.5 and 15 mg/kg groups, respectively, versus placebo. Most patients (62%) received multiple lines of poststudy treatment. Updated safety results are consistent with those previously reported.
3 S% V) X* K7 b) n" b6 C
Cisplatin Gemzar Avastin.PDF
(329.84 KB, 下载次数: 1141)
+ X6 F) H2 Y5 Z! J. f
华为网盘附件：
2 k. [# \+ e5 x$ @% W, V% l【华为网盘】ava.JPG
/ a/ n+ m( L1 b& x7 g, P) i |
11011102001537 )
显身卡
